NEW YORK, August 17, 2016 /PRNewswire/ --
Biotechnology is a risk-taking arena where investors either come out a winner or the other way around. The industry is involved in drug development and clinical researches that are intended to treat and cure various medical conditions. Stock-Callers.com takes a look at these equities and see how they performed at the closing bell on Tuesday, August 16, 2016: Anavex Life Sciences Corp. (NASDAQ: AVXL), Threshold Pharmaceuticals Inc. (NASDAQ: THLD), StemCells Inc. (NASDAQ: STEM), and Aratana Therapeutics Inc. (NASDAQ: PETX). Access these companies' trade alerts for free by signing up now at: Sign up today and download for free the research reports for the stocks covered today at: http://stock-callers.com/registration
Anavex Life Sciences
New York-based Anavex Life Sciences Corp.'s stock recorded a trading volume of 526,532 shares, and finished the trading session 6.21% lower at $3.32. Shares of the Company, which engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers, are trading below their 50-day moving average by 34.35%. The stock has a Relative Strength Index (RSI) of 39.06.
On August 11th, 2016, Anavex Life Sciences reported that net loss for Q3 2016 was approximately $2.2 million, or $0.06 per share, compared to a net loss of approximately $4.2 million, or $0.22 per share, for the same period in fiscal 2015. The company had cash and cash equivalents of approximately $9.7 million at June 30th, 2016, compared to approximately $15.3 million at September 30th, 2015. AVXL complete research report is just a click away at: http://stock-callers.com/registration/?symbol=AVXL
On Tuesday, South San Francisco, California headquartered Threshold Pharmaceuticals Inc.'s stock recorded a trading volume of 368,517 shares and ended the session 4.69% lower at $0.61. The Company's shares have gained 15.09% in the last one month, 64.86% over the previous three months, and 27.08% on an YTD basis. The stock is trading 15.75% above its 50-day moving average. Moreover, shares of Threshold Pharmaceuticals, which discovers and develops therapeutic agents that target tumor cells for the treatment of patients living with cancer in the US, have an RSI of 57.71.
On August 1st, 2016, Threshold Pharmaceuticals reported that net loss for Q2 2016 was $6.9 million compared to $8.3 million for the same period in 2015. The company noted that no revenue was recognized in Q2 ended June 30th, 2016, compared to $3.7 million for the same period of 2015. Cash, cash equivalents and marketable securities totaled $33.6 million at June 30th, 2016, compared to $38.0 million at March 31st, 2016. The complimentary report on THLD can be downloaded at: http://stock-callers.com/registration/?symbol=THLD
Newark, California headquartered StemCells Inc.'s stock ended the day 598.55% higher at $2.60. A total volume of 58.55 million shares was traded, which was above their three months average volume of 616,050 shares. The Company's shares have skyrocketed 584.21% in the last month. The stock is trading 550.25% above its 50-day moving average. Additionally, shares of StemCells, which engages in the research, development, and commercialization of cell-based therapeutics and related technologies, have an RSI of 95.63.
On August 16th, 2016, StemCells, and Microbot Medical Ltd., a private company organized under the laws of the State of Israel announced that they have entered into a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, as well as other conditions. The board of directors of each company has unanimously approved the terms of the merger agreement and has recommended that its shareholders approve the transaction. Sign up for your complimentary report on STEM at: http://stock-callers.com/registration/?symbol=STEM
Shares in Leawood, Kansas headquartered Aratana Therapeutics Inc. recorded a trading volume of 2.09 million shares, which was above their three months average volume of 630,370 shares. The stock ended the session 4.57% lower at $8.98. The Company's shares have surged 34.03% in the last month, 48.43% over the previous three months, and 60.93% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 27.18% and 56.88%, respectively. Furthermore, shares of Aratana Therapeutics, which focuses on the licensing, development, and commercialization of biopharmaceutical products for the companion animals worldwide, have an RSI of 67.10.
On August 15th, 2016, Aratana Therapeutics announced that the U.S. Food and Drug Administration's Center for Veterinary Medicine approved NOCITA® as a local post-operative analgesia for cranial cruciate ligament surgery in dogs. Aratana anticipates Nocita will be commercially available to veterinarians in the fall of 2016. Nocita is a long-acting, local anesthetic that lasts up to 72 hours post-surgery by releasing bupivacaine over time from multi-vesicular liposomes deposited in the tissue. Download the research report for free on PETX at: http://stock-callers.com/registration/?symbol=PETX
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://stock-callers.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA